

# **APPLICATION**

PLEASE CHEC	<b>KALL THAT AP</b>	PLY							
Patient's HIPAA author and representatives for an area of the presentatives for a second and a second area of the presentatives.		rizing the release of the (BV)	patien	t's identification and	insurar	nce informati	on to Sanofi	US, and their agent	ts
Reimbursement Connection (BV)								esource Connection	
☐ BV only (Complete sections 1-3) (No signatures required)			No cost medication program, Acceptable and patient signature page 2				Additional pa	dditional patient resources, atient signature required	
☐ BV and Patient Assistance (If no coverage is found, prescriber			required (Complete sections (Comple					sections 1-5)	
and patient signature required) (Complete sections 1-3, 5)			1-3, 5) SANOFI Soundation for North America						
1. PATIENT INFO	RMATION								
				ame:Gender: $\square$ M $\square$ F					
Address:	City:		r:	State:			Zip Code:		
Phone #:	Date of Birth:		Social Security #:				No Insurance? □		
Email Address:	Primary Language:						_		
Primary Insurance:			S	econdary Insurance	e:				
Policy #:				olicy #:					
Policy Holder Name:			Р	olicy Holder Name:					
Date of Birth:				ate of Birth:					
Insurance Phone #:				nsurance Phone #:					_
Group #:			G	Group #:					╛
2. TREATMENT A	AND PRESCRIB	ING INFORMATION	<b>V</b> (se	e instructions or	n pag	e 3 for ava	ailable pro	oducts)	
For Lantus® (insulin glarg medications used for the	ine injection) 100 U treatment of diabete	<i>nits/mL and/or Apidra</i> <sup>®</sup> es available in pen only	(insul	in glargine [rDNA or example is in the top	rigin] ii o line d	njection), ind of the table b	dicate vials below:	or pens. All other	
Drug: Lantus Solostar	3 ml   ICD/Dx:	Enter ICD-10 Code	Rx:	30 u BID	Qty:	90 days	Refills:	3	
Drug:	ICD/Dx:		Rx:		Qty:		Refills:		1
Drug:	ICD/Dx:		Rx:		Qty:		Refills:		1
Drug:	ICD/Dx:		Rx:		Qty:		Refills:		
3. PRESCRIBER	INFORMATION								
		Drogoribor Typ	.0:		0	tata whore	licenced:		
	Prescriber Type								
State License #:NPI #:Tax ID #:Physician Name (if different from Prescriber):State									
									_
Facility Name:		Facility Type: □ F	rescr	iber Office/Clinic	] Hosp	ital Outpatie	ent ⊟Hos	pital Inpatient	
Facility Address*:		C	ity:	Stat	te:		_Zip Code	:	_
*Sanofi product must be	· ·		-		-	-		· · · · · · · · · · · · · · · · · · ·	
Primary Contact Name:									_
Primary Phone #:	:Primary Fax #:			Primary Email:					_
I certify that the information provided is current, complete, and accurate to the best of my knowledge. I certify that the Sanofi product is medically necessary for this patient and that I am authorized under State law to prescribe and dispense the requested medication. I certify that I have obtained from my patient all required written authorization for the release of my patient's personal identification, medical and insurance information to Sanofi US and/or The Sanofi Foundation for North America and their agents and representatives. I understand that any information provided is for the sole use of the Program to verify my patient's insurance coverage, to assess, if applicable, patient's eligibility for participation in the patient assistance program and to otherwise administer the Sanofi Patient Connection program and related services. I understand that I am under no obligation to prescribe any Sanofi product and that I have not received nor will I receive any benefit from Sanofi or their agents or representatives for prescribing a Sanofi product. The facility address noted above in Section 3 is my office or hospital address. My signature certifies that any prescription products received from this Program will be used for the above named patient only and will not be resold nor offered for sale, trade or barter and will not be returned for credit, nor will payment be sought from any payer, patient or other source for product received from the Program.									
SIGN HERE Pres	criber Signature (require	ed – no stamps)		Printed I	Name			Date	-

4. RESOURCE CONNECTION
Does the patient wish to have the program contact them to help identify resources provided by other organizations?
☐ Yes (Patient signature required below) ☐ No
If yes, please mark which resources the patient may be interested in if available:
☐ Clinical Support Services ☐ Transportation ☐ Patient Advocacy Support ☐ Nutritional Supplements (groceries, food banks, etc.)
☐ Health Supplies/Cosmetic Aids (wigs, scarves, etc.) ☐ Home Care Services (shelter, utilities, etc.) ☐ Other:
5. PATIENT ASSISTANCE CONNECTION (certification and authorization to disclose information)
Total # of people in the household: □1 □2 □3 □4 □5 □ Other:Annual Household Income: \$
<b>Income Verification:</b> Sanofi Patient Connection and its authorized third party agents will use my date of birth or social security number and/or additional demographic information as needed to access my credit information and information derived from public and other sources to estimate my income in conjunction with the eligibility determination process. As a soft credit inquiry, this option will not impact my credit score. Sanofi Patient Connection and its authorized third party agents reserve the right to ask for additional documents and information at any time.
Patient Name (Please Print): I,
Representative/Organization: Relationship: Phone #:
SIGN HERE  Patient Signature  Printed Name  Date
APPLICATION CHECKLIST (application will be delayed if all information is not received)
■ HIPAA consent checked or provider signature included
■ The following must be completed as needed: Dosage, Diagnosis Code, State License Number, Insurance Details
☐ Signatures of prescriber and patient (required for Patient Assistance Connection)

Signature of patient (required for Resource Connection)

#### PRODUCT SELECTION (please enter desired product in Section 2 for all services)

- Adacel<sup>®</sup> (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed)
- Adlyxin<sup>®</sup> (lixisenatide) injection
- Apidra® (insulin glulisine [rDNA origin] injection)
- Clolar® (clofarabine) Injection
- Elitek® (rasburicase)\*
- Imogam<sup>®</sup> Rabies-HT Immune Globulin, [Human] USP, Heat Treated
- Imovax® Rabies Vaccine [Human Diploid Cell]
- Jevtana<sup>®</sup> (cabazitaxel) Injection\*
- Lantus® (insulin glargine injection) 100 Units/mL
- Leukine<sup>®</sup> (sargramostim)
- Lovenox<sup>®</sup> (enoxaparin sodium injection)\*

- Menactra<sup>®</sup> Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine
- Menomune<sup>®</sup> (Meningococcal Polysaccharide Vaccines Groups A, C,Y and W-135 combined)
- Mozobil<sup>®</sup> (plerixafor injection)
- Multaq<sup>®</sup> (dronedarone) Tablets\*
- Priftin® (rifapentine) Tablets
- SOLIQUA® 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL and 33 mcg/mL
- Tenivac<sup>®</sup> (tetanus and diphtheria toxoids adsorbed)
- Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)]
- Toujeo<sup>®</sup> (insulin glargine injection) 300 units/mL
- Zaltrap<sup>®</sup> (ziv-aflibercept)\*

\*Please see full U.S. prescribing information, including Black Box warning.

Full U.S. prescribing information for all Sanofi Patient Connection supported products can be accessed at www.visitspconline.com.

## PATIENT ASSISTANCE CONNECTION ELIGIBILITY REQUIREMENTS

- · An application must be submitted for each patient.
- Patient must be a U.S. citizen or resident and be under the care of a licensed healthcare provider authorized to prescribe, dispense and administer medicine in the U.S. (State License Number is required in Section 3).
- Patient must have no insurance coverage or not have access to the prescribed product or treatment via their insurance.
- If a patient has Medicare Part D coverage they can be assessed for patient assistance eligibility by meeting these criteria:
  - Not be eligible for Low Income Subsidy (LIS)
  - Not have coverage for a generic equivalent product
  - Have an out-of-pocket (OOP) total drug spend of 5% of their annual income
- If a patient appears to be eligible for Medicaid they may be required to provide documentation of Medicaid denial before being assessed for patient
  assistance eligibility.
- · Patient must meet the following financial criteria:
  - Annual household income of ≤250% of the current Federal Poverty Level\* for all non-Oncology/non-Hematology products
  - Annual household income of ≤500% of the current Federal Poverty Level\* for all Oncology and Hematology products
- If applying for Drug Replacement (Lovenox, Oncology and Hematology products only), a copy of the claim, denial, flow sheet(s) and drug dispensing log
  (with patient name, date of service, product NDC/Lot#, total dosage) must be submitted.
- For Vaccines, patient must be 19 years of age or older (except for IMOVAX RABIES and IMOGAM RABIES HT).

\*To assess current Federal Poverty Level details, visit: http://aspe.hhs.gov.



#### **ADDITIONAL INFORMATION**

- · A representative from Sanofi may contact you for follow-up on any adverse event you may report regarding a Sanofi product.
- Sanofi Patient Connection is also pleased to provide you with access to the "SPC Education Center" by calling 855.977.2338 (855.9SPCEDU), Monday through Friday, 9:00am to 8:00pm ET. You can speak to a live counselor dedicated to:
  - Providing information about local healthcare reform related resources
  - Directing you to either the federal or state-run Health Insurance Marketplace

## FORM SUBMISSION OPTIONS



Secure Provider Portal www.visitspconline.com



**Fax** 1.888.847.1797



U.S. Mail

